Drug General Information |
Drug ID |
D0F9QT
|
Former ID |
DNC008996
|
Drug Name |
A-987306
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H25N5O
|
Canonical SMILES |
C1CCC2C(C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N
|
InChI |
1S/C18H25N5O/c19-18-21-16-12(17(22-18)23-9-7-20-8-10-23)5-6-14-15(16)11-3-1-2-4-13(11)24-14/h11,13,20H,1-10H2,(H2,19,21,22)/t11-,13+/m0/s1
|
InChIKey |
DJKJVWJQAVGLHJ-WCQYABFASA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
Muscarinic acetylcholine receptor M4 |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 2B receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine receptor 3A |
Target Info |
Inhibitor |
[1]
|
D(3) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
Muscarinic acetylcholine receptor M3 |
Target Info |
Inhibitor |
[1]
|
C-C chemokine receptor type 1 |
Target Info |
Inhibitor |
[1]
|
NK-2 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Vasopressin V1a receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 1B receptor |
Target Info |
Inhibitor |
[1]
|
Muscarinic acetylcholine receptor M1 |
Target Info |
Inhibitor |
[1]
|
Muscarinic acetylcholine receptor M2 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Calcium signaling pathway
|
Neuroactive ligand-receptor interaction
|
Gap junction
|
Serotonergic synapse
|
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway
|
Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
Cholinergic synapse
|
Regulation of actin cytoskeletonhsa04020:Calcium signaling pathway
|
Inflammatory mediator regulation of TRP channelshsa04726:Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
Dopaminergic synapsehsa04020:Calcium signaling pathway
|
Regulation of actin cytoskeleton
|
Insulin secretion
|
Salivary secretion
|
Gastric acid secretion
|
Pancreatic secretionhsa04060:Cytokine-cytokine receptor interaction
|
Chemokine signaling pathwayhsa04020:Calcium signaling pathway
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Sphingolipid signaling pathway
|
Morphine addictionhsa04020:Calcium signaling pathway
|
Vascular smooth muscle contractionhsa04024:cAMP signaling pathway
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
PI3K-Akt signaling pathway
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
TCR Signaling Pathway
|
IL2 Signaling Pathway
|
TNFalpha Signaling Pathway
|
Leptin Signaling PathwayNetPath_11:TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04375:5HT3 type receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00031:Inflammation mediated by chemokine and cytokine signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
|
PathWhiz Pathway
|
Gastric Acid ProductionPW000564:Muscle/Heart Contraction
|
Reactome
|
Serotonin receptors
|
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (q) signalling eventsR-HSA-975298:Ligand-gated ion channel transportR-HSA-390651:Dopamine receptors
|
Acetylcholine regulates insulin secretion
|
G alpha (q) signalling eventsR-HSA-380108:Chemokine receptors bind chemokines
|
G alpha (i) signalling eventsR-HSA-416476:G alpha (q) signalling eventsR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-388479:Vasopressin-like receptors
|
G alpha (q) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
SIDS Susceptibility Pathways
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
Calcium Regulation in the Cardiac Cell
|
Regulation of Actin Cytoskeleton
|
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
GPCR downstream signalingWP706:SIDS Susceptibility Pathways
|
Iron uptake and transportWP58:Monoamine GPCRs
|
Nicotine Activity on Dopaminergic Neurons
|
GPCRs, OtherWP58:Monoamine GPCRs
|
Integration of energy metabolism
|
GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like
|
Peptide GPCRs
|
GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
|
Secretion of Hydrochloric Acid in Parietal Cells
|
GPCRs, Other
|
References |
REF 1 | J Med Chem. 2008 Nov 27;51(22):7094-8.cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. |